NZ607103A - A water-in-oil type emulsion for treating a disease of the eye - Google Patents

A water-in-oil type emulsion for treating a disease of the eye

Info

Publication number
NZ607103A
NZ607103A NZ607103A NZ60710311A NZ607103A NZ 607103 A NZ607103 A NZ 607103A NZ 607103 A NZ607103 A NZ 607103A NZ 60710311 A NZ60710311 A NZ 60710311A NZ 607103 A NZ607103 A NZ 607103A
Authority
NZ
New Zealand
Prior art keywords
eye
water
type emulsion
disease
treating
Prior art date
Application number
NZ607103A
Inventor
Frédéric Lallemand
Jean-Sébastien Garrigue
Betty Philips
Original Assignee
Santen Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10175337.4A external-priority patent/EP2425814B1/en
Priority claimed from US12/875,805 external-priority patent/US20120058187A1/en
Application filed by Santen Sas filed Critical Santen Sas
Publication of NZ607103A publication Critical patent/NZ607103A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided is a composition comprising a water-in-oil type emulsion comprising an oil phase, a lipophilic surfactant dissolved in the oil phase, an aqueous phase dispersed in the oil phase and a hydrophilic therapeutic agent dissolved in the aqueous dispersed phase. The composition is for intraocular injection to treat diseases or medical conditions of the eye.
NZ607103A 2010-09-03 2011-09-02 A water-in-oil type emulsion for treating a disease of the eye NZ607103A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10175337.4A EP2425814B1 (en) 2010-09-03 2010-09-03 A water-in-oil type emulsion for treating a disease of the eye
US12/875,805 US20120058187A1 (en) 2010-09-03 2010-09-03 Water-in-oil type emulsion for treating a disease of the eye
PCT/EP2011/065236 WO2012028733A1 (en) 2010-09-03 2011-09-02 A water-in-oil type emulsion for treating a disease of the eye

Publications (1)

Publication Number Publication Date
NZ607103A true NZ607103A (en) 2015-09-25

Family

ID=45772196

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ607103A NZ607103A (en) 2010-09-03 2011-09-02 A water-in-oil type emulsion for treating a disease of the eye

Country Status (16)

Country Link
EP (1) EP2611414B1 (en)
JP (1) JP5829685B2 (en)
KR (1) KR101777824B1 (en)
CN (1) CN103140216B (en)
AU (1) AU2011298298B2 (en)
BR (1) BR112013004570A2 (en)
CA (1) CA2809460C (en)
EA (1) EA028375B1 (en)
ES (1) ES2524580T3 (en)
GE (1) GEP201706606B (en)
HK (1) HK1186660A1 (en)
MX (1) MX2013002115A (en)
MY (1) MY157513A (en)
NZ (1) NZ607103A (en)
SG (1) SG188272A1 (en)
WO (1) WO2012028733A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011320345C1 (en) 2010-10-29 2017-04-06 Cohesive Technologies Inc. LC-MS configuration for purification and detection of analytes having a broad range of hydrophobicities
TW201609145A (en) * 2013-12-25 2016-03-16 參天製藥股份有限公司 Injectable agent and depot formation method
EA035620B1 (en) 2014-08-11 2020-07-16 Борд Оф Сьюпервайзорз Оф Луизиана Стэйт Юниверсити Энд Эгрикалчурал Энд Мекэникал Колледж Methods and composition for treating or preventing cataract
EP3881829A1 (en) * 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
CN109260458B (en) * 2017-07-18 2022-03-18 百捷生物科技有限公司 Application of collagen implant in preparation of glaucoma surgery auxiliary restoration material
KR102048940B1 (en) 2017-12-06 2019-11-26 주식회사 커스토메이드 Cable feeding apparatus with cable guide
CN108283622A (en) * 2018-04-03 2018-07-17 广州君博医药科技有限公司 A kind of slow-release Linezolid eye medicinal and preparation method thereof
AU2019263302B2 (en) * 2018-05-01 2024-06-27 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
EP4321152A1 (en) * 2021-04-08 2024-02-14 Tionlab Therapeutics Sustained-release lipid pre-concentrate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318539B1 (en) 2000-05-26 2003-08-27 Italfarmaco Spa PROLONGED RELEASE PHARMACEUTICAL COMPOSITIONS FOR THE PARENTERAL ADMINISTRATION OF BIOLOGICALLY HYDROPHILE SUBSTANCES
US6417237B1 (en) * 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
EP1485066B1 (en) * 2002-03-12 2016-09-21 Ethypharm Composition having gelling properties for the prolonged delivery of bioactive substances
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
EP1867323A1 (en) * 2006-06-13 2007-12-19 Farmatron Ltd. Pharmaceutical compositions with biological barriers permeation enhancing properties
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US20110182877A1 (en) 2007-10-02 2011-07-28 Potentia Pharmaceuticals, Inc. Sustained delivery of compstatin analogs from gels

Also Published As

Publication number Publication date
SG188272A1 (en) 2013-04-30
JP2013536829A (en) 2013-09-26
WO2012028733A1 (en) 2012-03-08
CN103140216A (en) 2013-06-05
KR101777824B1 (en) 2017-09-26
MY157513A (en) 2016-06-15
JP5829685B2 (en) 2015-12-09
KR20130101051A (en) 2013-09-12
AU2011298298A1 (en) 2013-03-14
EP2611414A1 (en) 2013-07-10
EA201300314A1 (en) 2013-11-29
AU2011298298B2 (en) 2016-04-21
MX2013002115A (en) 2013-06-28
EP2611414B1 (en) 2014-11-12
EA201300314A8 (en) 2017-08-31
GEP201706606B (en) 2017-01-25
EA028375B1 (en) 2017-11-30
CN103140216B (en) 2015-07-15
HK1186660A1 (en) 2014-03-21
CA2809460A1 (en) 2012-03-08
CA2809460C (en) 2018-12-11
BR112013004570A2 (en) 2016-09-06
ES2524580T3 (en) 2014-12-10

Similar Documents

Publication Publication Date Title
NZ607103A (en) A water-in-oil type emulsion for treating a disease of the eye
SMT201300101B (en) An emulsion of the water in oil type for the treatment of an eye disease
AR121843A2 (en) OPHTHALMIC FORMULATION AND METHOD TO IMPROVE PRESBYOPIA
AR088585A1 (en) A MEDICINAL PRODUCT TO TREAT THE PREVIOUS EYE DISEASE
BR112016000546A2 (en) methods to treat or prevent eye conditions
CR20120638A (en) METHODS OF COMBINED THERAPY TO TREAT PROLIFERATIVE DISEASES
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
BR112016015763B8 (en) pharmaceutical preparation including pyridylaminocetic acid compound, and, use of the same
BR112014008789A2 (en) prevention and treatment of eye conditions
GB2540638A8 (en) Compositions, Formulations and methods for treating ocular diseases
BR112014014783A2 (en) jnk inhibitor molecules for treating various diseases
EA201500364A1 (en) TREATMENT OF EYE DISEASES
BR112014014378A2 (en) composition and use to treat eye disease related to nucleic acid
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
MX355770B (en) Pharmaceutical composition of ibuprofen and tramadol for ophthalmological use.
BR112014031154A2 (en) prophylactic and / or therapeutic agent for mild cognitive impairment; and interstitial flow enhancing agent
MX2018001918A (en) Quantitative peri-orbital application of ophthalmology drugs.
PH12014501296A1 (en) Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
WO2015094019A3 (en) Pharmaceutical preparation for preventing and treating progressive myopia
MXJL06000001A (en) Method of preparing an aqueous meloxicam solution and aqueous solution thus produced.
BR112015022084A2 (en) compositions for use in treating eye disorders with the use of dipyridamole
Kachalina et al. Epiretinal fibrosis: pathogenesis, outcomes, treatment methods
CL2011001812A1 (en) Use of deferiprone to prevent and treat an iron-related eye disorder selected from: age-related macular degeneration, glaucoma, cataracts, diabetic retinopathy, hereditary retinal degeneration, retinal detachment, ischemic retinopathy, among others.
EA201690903A1 (en) TREATMENT GLAUCOMA USING LAQUINIMODE
BR112014016640A2 (en) composed of double-stranded RNA for casp2 and its uses

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 SEP 2018 BY DENNEMEYER + CO.

Effective date: 20160321

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 SEP 2019 BY DENNEMEYER + CO

Effective date: 20180821

LAPS Patent lapsed